Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients. Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy.

Trial Details

NCT ID

NCT04666961

Phase

PHASE2

Sponsor

Institut Cancerologie de l'Ouest

Status

RECRUITING

Cancer Type

Lobular Carcinoma Breast Cancer

Interventions

Tamoxifen 20 mg
Anastrozole 1Mg Tab

Locations (sample)

Angers, France|47.47156,-0.55202
Bordeaux, France|44.84124,-0.58046
Montpellier, France|43.61093,3.87635
Nice, France|43.70313,7.26608
Paris, France|48.85341,2.3488

Key Eligibility Criteria

Patient ≥ 40 years old
Histological diagnosis of ductal carcinoma in situ without infiltrating contingent
Clinical T0N0
Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lobular Carcinoma Breast Cancer Trials on Trialify →